Eliquis demonstrated superiority in the primary safety endpoint of major

Eliquis demonstrated superiority in the primary safety endpoint of major
For patients receiving ELIQUIS doses greater than 2.5 mg twice daily, the dose of ELIQUIS should be decreased by 50% when it is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, ritonavir, …
Read more on Business Wire (press release)

Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at European
For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA. For patients with severe renal impairment (CrCl …
Read more on SYS-CON Media (press release)

Posted in Pet Care Media | Tagged , , , , , , | Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>